Previously we reported significant associations of the human leukocyte antigen (HLA)-DPB1 05:01 with memory against hepatitis B (HB) vaccination. However, the effects of HLA-DPB1 on antibodies to hepatitis B surface antigen (anti-HBs) kinetics were not explored. We followed up a cohort of 1974 HB booster recipients and quantified their 1-month and 1-year post-booster anti-HBs titers. A total of 681 subjects were randomly selected and typed for HLA-DPB1. We found that male subjects, undetectable prebooster titers, and 05:01 homozygotes led to significantly lower post-booster anti-HBs titers. The geometric means (95% confidence interval (CI)) of 1-month post-booster anti-HBs titers were 4.68 (2.69-8.12), 23.01 (14.96-35.40) and 50.06 (27.20-92.13) mIU ml À 1 for subjects carrying two, one and no HLA-DPB1 05:01 allele. The corresponding figures for 1-year post-booster anti-HBs titers were 1.26 (0.73-2.18), 4.72 (3.08-7.25) and 7.32 (3.75-13.56) mIU ml À 1 . There were significant associations of post-booster anti-HBs titers with the number of HLA-DPB1 risk and protective alleles. Among booster responders, anti-HBs decay rates were significantly reduced in subjects who had detectable pre-booster anti-HBs titers and the HLA-DPB1 05:01 allele. Our results indicated that HLA-DPB1 influences the kinetics of anti-HBs. The long-term memory against hepatitis B surface antigen (HBsAg) and the residual serum titers of anti-HBs after HB vaccination may be influenced by different mechanisms as evidenced by their inverse trend of associations with the 05:01 allele.
INTRODUCTION
The Hepatitis B virus (HBV) is estimated to have infected more than two billion people around the world, and more than 350 million of them are chronically infected. 1, 2 The infection may lead to the development of serious liver diseases such as cirrhosis, liver failure or hepatocellular carcinoma. [3] [4] [5] In the 1980s, hepatitis B (HB) vaccination with the major surface protein of HBV was introduced and has been the primary means of preventing infection. In Taiwan, the universal HB vaccination program has been successful in reducing the HBV infection rate since 1986. [6] [7] [8] [9] However, breakthrough and chronic HBV infections in vaccinated children even when a booster is applied indicate the need to further explore the determinants of long-term responses to vaccination. [10] [11] [12] The possible association of human leukocyte antigens (HLAs) with HBV vaccination was first indicated when a study compared HLA types in responders with those in non-responders. 13 Several studies have identified variants in HLA-A, B, C, DR and DQ loci to be correlated with responsiveness to HB vaccination. [14] [15] [16] [17] Revaccination studies in Taiwan found that HLA-A, B and DR had significant effects on response to booster HB vaccination. 18, 19 However, there was no report regarding the association of HLA-DP with HB vaccination response until our previous study in which we analyzed the frequencies of HLA-DPB1 allele and genotype in antibodies to hepatitis B surface antigen (anti-HBs) in seronegative adolescents and assessed its effects on the short-term response to booster HB vaccination. 20 We found that DPB1 05:01and 09:01 alleles significantly increase the likelihood of undetectable post-booster anti-HBs titers. In contrast, DPB1 02:01:02, 02:02, 03:01:01, 04:01:01 and 14:01 alleles correlated with significantly decreased likelihood. After adjustment for pre-booster anti-HBs titers, the odds ratio (OR) of these risk or protect alleles remained significant, which indicated the presence of independent effects of these alleles. However, the effects of these alleles on the kinetics of anti-HBs were not explored before.
In the present study, we tested an adolescent cohort of 1974 HB booster recipients who had received primary HB vaccination during infancy but failed to show anti-HBs titers X10 mIU ml À 1 at the age of 15-18 years. We followed up their anti-HBs titers 1 month and 1 year after booster administration. A random sample of 681 subjects was typed for HLA-DPB1. Using regression analyses, we identified factors associated with low booster response and verified the importance of HLA-DPB1. We also assessed the effect of HLA-DPB1 on the decay rate of post-booster anti-HBs titers.
RESULTS

Characteristics of study subjects
The characteristics of the 681 study subjects are shown in Table 1 . The majority (62.1%) of subjects were male. The mean age at enrollment was 15.58 years and the mean time interval from the reception of the last vaccine to the date of enrollment was 14.53 years. All subjects received and completed the HB vaccination series during infancy with a median age of 6 days for the first vaccine and 1.05 years for the last vaccine. The study subjects were comparable to the whole revaccination cohort for all baseline characteristics, except for the inclusion of more male students in the study.
All recruited subjects had a pre-booster anti-HBs titer of o10 mIU ml À 1 , and nearly 60% of them had anti-HBs titer lower than the detection limit (1.0 mIU ml À 1 ). One month after booster administration, there were still 383 (56.3%) subjects who had anti-HBs o100 mIU ml À 1 , and 283 (41.6%) of them had o10 mIU ml
. In the booster recipient cohort, 646 (94.9%) booster recipients had a 1-year blood sample for anti-HBs quantification. Among them, 521 (80.7%) and 344 (53.3%) subjects had anti-HBs levels o100 mIU ml À 1 and o10 mIU ml À 1 , respectively. Among 398 booster responders, 373 (93.7%) had 1-year post-booster blood samples for anti-HBs titers quantification, and 112 (30.4%) had anti-HBs titers that dropped to less than 1/10 in 1 year and were categorized as fast anti-HBs decay.
Univariate analysis for 1-month post-booster anti-HBs titer In our previous study, we discovered the association of HLA-DPB1 alleles with HB booster responses and found that HLA-DPB1 05:01 was strongly correlated with non-response to the HB booster vaccine. 20 To further assess the effect of the HLA-DPB1 05:01 allele over time, we performed univariate analyses for 1-month and 1-year post-booster anti-HBs titers. As there were almost complete associations for the HLA-DPB1 05:01 genotypes with the numbers of cluster I (w P ¼ 2.26 Â 10 À 274 ) alleles, our analyses for HLA-DPB1 with postbooster anti-HBs titers were primarily focused on HLA-DPB1 05:01 genotypes. Table 2 shows that the geometric mean titers (GMTs) of 1-month post-booster anti-HBs titers were significantly lower in male subjects and in subjects who had pre-booster anti-HBs titers of o1.0 mIU ml À 1 or who carried the HLA-DPB1 05:01 allele. The percentage of low anti-HBs individuals was also significantly greater among male subjects (47.0% and 19.4% for anti-HBs levels o10 and 10-99.9 mIU ml À 1 , respectively) compared with female subjects (32.6% and 7.0%, respectively; both Po0.0001). The pre-booster anti-HBs titer was a strong predictor for post-booster anti-HBs titer. Approximately two-thirds of subjects with a pre-booster titer of o1.0 mIU ml À 1 had postbooster titers o10 mIU ml . On the other hand, most subjects (75.6%) who had a pre-booster titer of 1.0-9.9 mIU ml À 1 raised their post-booster titer to 4100 mIU ml À 1 . The subjects with homologous 05:01 genotype had significantly lower 1-month post-booster anti-HBs titer compared with heterozygotes or those with other alleles (GMTs: 4.68 mIU ml , respectively; Po0.0001). The homozygosity effect was also evident when the percentage of subjects with post-booster titers X100 mIU ml À 1 increased by 50% in the heterozygous group (47.3 vs 30.1%).
Univariate analysis for 1-year post-booster anti-HBs titer The results of 1-year follow-up of the cohort members are shown in Table 3 . The 1-year post-booster GMTs for female subjects and for those who had pre-booster titers of 1.0-9.9 mIU ml À 1 were significantly higher than those for male subjects and for those who had pre-booster titers of o1.0 mIU ml À 1 , respectively (both Po0.0001). Nearly 90% of male subjects had post-booster anti-HBs titers o100 mIU ml À 1 , whereas almost 70% of female subjects had their anti-HBs in the same range. Among subjects who had pre-booster titers o1.0 mIU ml À 1 , 77.1% had postbooster titers o10 mIU ml À 1 . The corresponding figure for subjects with pre-booster titers of 1.0-9.9 mIU ml À 1 was 18%. The proportion of 1-year post-booster anti-HBs titers o10 mIUml À 1 was also significantly higher in subjects of 05:01 homozygotes in comparison with the 05:01 heterozygotes or other genotypes (66.1, 48.9, and 43.0%, respectively; Po0.0001).
Multivariate linear regression for post-booster anti-HBs titer
To further analyze the effects of HLA-DPB1 on the short-term kinetics of anti-HBs, we performed multivariate linear regression for post-booster anti-HBs titer. Table 4 shows that male subjects and those who had pre-booster anti-HBs titers o1.0 mIU ml
had significantly lower levels of post-booster anti-HBs titers. The adjusted regression coefficients depicted that the gender differences in the 1-month and 1-year post-booster anti-HBs titers were similar. As compared with subjects who did not carry the HLA-DPB1 05:01 allele, the post-booster anti-HBs titers were significantly lower for subjects of 05:01 homozygotes. The adjusted regression coefficients depicted are À 0.727 (Po0.001) and À 0.504 (Po0.001) for 1-month and 1-year post-booster antiHBs titers, respectively. Subjects who had two cluster II alleles had significantly lower post-booster anti-HBs titers than those who had none of these alleles. The HLA-DPB1 05:01 heterozygote or subjects who had only one cluster II allele did not have lower postbooster anti-HBs titers. In contrast, there were significant linear trends for post-booster anti-HBs titers with the number of cluster I alleles (both Po0.001). As compared with subjects who had no cluster I allele, the adjusted regression coefficients for 1-month post-booster anti-HBs titers were 0.591 (Po0.001) and 0.875 (Po0.001) for those who had one and two cluster I alleles, respectively. The corresponding figures for 1-year post- Abbreviations: HB, Hepatitis B; s.d., standard deviation.
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booster anti-HBs titers were 0.574 (Po0.001) and 0.800 (Po0.001), respectively.
Logistic regression for fast anti-HBs decay Table 5 shows that, compared with subjects with undetectable pre-booster anti-HBs titers, the post-booster anti-HBs titers waned significantly slower in subjects with detectable pre-booster antiHBs titers (adjusted-OR ¼ 0.61, 95% confidence interval (CI): 0.39-0.97). The presence of the HLA-DPB1 05:01 allele was significantly correlated with the lower likelihood of fast anti-HBs decay, with an adjusted OR of 0.61 (95% CI: 0.38-1.00).
The adjusted ORs for HLA-DPB1 05:01 heterozygotes or for subjects who had only HLA-DPB1 1 cluster II allele were both significantly decreased and nonsignificantly decreased for the 05:01 homozygote or for subjects who had two cluster II alleles. The numbers of cluster I alleles were not correlated with the antiHBs decay rate. No significant association was found for other HLA-DPB1 alleles (Supplementary Table S1 ).
DISCUSSION
In the present study, we determined 1-month and 1-year postbooster anti-HBs titers in 681 anti-HBs-seronegative adolescents who had received complete primary HB vaccination during infancy. We dissected the roles of previously identified risk and protective HLA-DPB1 alleles. We found that 05:01 homozygotes had significantly reduced post-booster anti-HBs titers and its effect was compensated by the presence of other alleles in heterozygotes. As a result of the almost complete associations with the HLA-DPB1 05:01 genotypes, we found that there were significantly positive and negative trends for post-booster anti-HBs titers with the numbers of HLA-DPB1 cluster I and II, respectively. Additionally, the HLA-DPB1 05:01 allele was also significantly associated with a slow anti-HBs decay rate. To the best of our knowledge, we are the first to report the role of the HLA-DPB1 allele in response to HBV booster vaccination.
The role of HLA-DP in association with HBV was first demonstrated in a genome-wide association study. 21 With the power of a large sample, Kamatani et al. reported significant association of the HLA-DP locus with the likelihood of HBV chronic infection in Japanese and Thai populations. Following similar studies confirmed the association of HLA-DP with chronic HB in other populations. [22] [23] [24] In our previous study, we were the first to identify risk and protective HLA-DP alleles in association with the risks of non-response to HB vaccination. 20 In the present study, we further confirmed the associations of the same risk and protective alleles on 1-year post-booster vaccination anti-HBs titers.
The HLA-DP is a locus of class II HLA, which is expressed in antigen-presenting cells to present extracellular antigens to CD4 
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HLA-DR-DQ in HB virus infection. 26 They determined HLA class I and II alleles in 632 Gambian subjects and compared their status of HBV infection with HLA genotypes. They found no significant advantage for HLA-A, -B or -C heterozygotes. On the contrary, the likelihood of persistent HBV infection was significantly reduced for HLA-DR and HLA-DQB heterozygotes. The corresponding ORs were 0.62 (P ¼ 0.02) and 0.65 (P ¼ 0.02), respectively. However, the role of HLA-DP was not determined in their study. Heterozygote advantage was later discovered in other virus infections including HIV and HCV. 27, 28 In HIV, infected subjects with HLA heterozygosity of class I loci had delayed onset of acquired immunodeficiency syndrome. 27 In HCV, there were significantly lower proportions of HLA-DRB1 heterozygosity among infected subjects than among uninfected ones. 28 However, no report analyzed the effects of homozygosity in a single allele until our reports.
The encounter of a person with HBV triggers complex responses of a network of cells in the anti-viral adaptive immune response. Participating cell types include CD4 þ helper T cells, which produce cytokines to regulate inflammation and are required for the efficient development of effector cells such as CD8 þ cytotoxic T cells and antibody-producing B cells. 29 Cytotoxic T cells recognize HBV-infected cells and clear them through cytolytic and non-cytolytic mechanisms. 30, 31 Anti-HBs produced by B cells neutralize free viral particles and prevent reinfection. 32, 33 Activated effector cells may differentiate into memory cells to provide quick protective response for future contact with HBV. All cells must work in a coordinated manner to clear HBV and prevent chronic infection. The whole process is initiated by antigen HLA-DPB1 and anti-HBs titers kinetics T-W Wu et al presentation to CD4 þ cells with predominantly HLA class II molecules. The same process is also critical for successful vaccine responses. It is indicated that the response to booster vaccination is a function of memory cells. 34 In our study, we found that HLA-DPB1 is associated with undetectable post-booster anti-HBs titers, a surrogate of no or very low hepatitis B surface antigen (HBsAg)-specific memory.
Gender difference was another factor found to affect the responsiveness of booster in this study. We found that female subjects had significantly stronger booster responses compared with male subjects. In the immune system, a gender gap has long been observed clinically. 35 In humans, female subjects usually expressed higher level of antibodies and antibody-stimulating Th2 cytokines. 36, 37 They also had higher chances to develop autoimmune diseases because of a more responsive immune system. 35 Our finding was consistent with previous studies, including a recent large-scale HBV vaccination cohort study. 38 Sexual dimorphism can be introduced by the level of sex hormones or by the differential expression of sex chromosome genes. The expression of sex hormone receptors indicated the possible roles of sex hormones in regulating the functions of key immune cell types mentioned above. Both androgen and estrogen receptors were detected in B cells. 39 In T cells, only estrogen receptor was found in CD8 þ cells and no sex hormone receptors were found in CD4 þ cells. 40 Estrogen has been shown to raise antibody production, increase antigen presentation and enhance B-cell survival and maturation. 39, 41, 42 Relatively few studies have addressed the effects of sex chromosome genes because of the complexity of sex chromosome regulation. Palaszynski et al. created mice that had different sex chromosome combinations while having the same gonads by moving the testis determinant gene, Sry, from the Y chromosome to an autosome. 43 They found that mice with XX chromosomes develop more severe autoimmune diseases. 44 In the study, we unexpectedly found that the HLA-DPB1 05:01 allele is correlated with a slower decay rate of post-booster antiHBs titers, which seemed inconsistent with its role in HBsAgspecific memory. However, several lines of evidence have indicated that memory cells and plasma cells are subject to distinct regulatory mechanisms and contribute to the persistence of humoral immunity by independent processes. For instance, the number of antigen-specific memory B cells does not always correlate with concentrations of antigen-specific antibodies in serum. 45, 46 Similarly, serum titers of antigen-specific antibodies are basically unchanged in patients treated with the anti-CD20 monoantibody. 47 It is suggested that antibody titers after vaccination are primarily dependent on the number of plasma cells but not on memory cells. 34 Plasma cells are not intrinsically long-lived. [48] [49] [50] Recently, several factors were found to be associated with the long-term survival of plasma cells. [51] [52] [53] It is of scientific merit to further explore the relationships between these factors and HLA-DPB1.
In conclusion, we found that the homozygosity of HLA-DPB1 05:01 was highly associated with its risk effect, which could be compensated by the presence of other alleles. The trends of 1-month and 1-year post-booster anti-HBs titers with the numbers of HLA-DPB1 05:01, risk and protective alleles were consistent. Our present study provided important information for developing a potential patch strategy for those who are not responding to current HB vaccine or who cannot sustain high levels of anti-HBs after HB vaccination. It can help reduce the infection rate and establish better control of the disease.
MATERIALS AND METHODS
The study population
The study protocols were approved by the Institutional Review Board of Tzu Chi Medical Center and Taipei Medical University. Subjects who met the criteria of this study were recruited from our previous study. 12 In brief, an invitation letter coupled with a short questionnaire and informed consent form was delivered to 10 648 freshmen of seven public senior high schools from October 2003 to May 2008 in Hualien County, Taiwan, and a total of 8733 subjects were recruited in a sero-epidemiological study on HBV markers. Consenting students were asked to provide their vaccination record and were assayed for serum HBsAg and antibodies to HBsAg (anti-HBs).
A total of 2057 enrollees of the previous sero-epidemiological study and meeting the following criteria were further administered a booster dose of 20-mg HB vaccine (Engerix-B, GlaxoSmithKline Biologicals, Rixensart, Belgium): seronegative for both anti-HBs and HBsAg; received complete (X3 doses) HB vaccine during infancy; and did not receive any booster HB vaccination. One pre-booster (on the day of booster administration) and two post-booster (1 month and 1 year after) blood samples were obtained from each recipient for anti-HBs quantification. Eighty-three subjects who did not provide post-booster blood samples and had residual anti-HBs titers X10 mIU ml À 1 or antibodies to hepatitis B core antigen seropositivity in the pre-booster blood samples were excluded, leaving a total of 1974 subjects in the cohort of booster HB recipients. A sample of 681 subjects were randomly selected for the HLA-DPB1 study. 20 
Serologic testing
HBsAg and antibodies to hepatitis B core antigen serostatus of the prebooster blood samples were assayed by microparticle enzyme immunoassays with commercial kits AxSYN HBsAg (V2) and AxSYN CORE (Abbott Diagnostics, Chicago, IL USA), respectively. Anti-HBs titers in pre-and postbooster blood samples were assayed by a quantitative method with commercial kit AxSYN AUSAB (Abbott Diagnostics). The detection limit of this quantitative method was 1.0 mIU ml HLA-DPB1 and anti-HBs titers kinetics T-W Wu et al
HLA-DPB1 typing
The polymorphic second exon of HLA-DPB1 was determined by a sequencing-based typing method as described before. 20 In brief, exon 2 of HLA-DPB1 was amplified by polymerase chain reaction with a locusspecific primer set proposed by the International Histocompatibility Working Group. 54 Genotype ambiguities were resolved by selective amplification using group-specific primer sets. 55 The sequencing reaction was performed in both directions using Big Dye terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and automated ABI 3730 sequencer (Applied Biosystems).
Definitions
In the present study, we defined responders and non-responders as those who had 1-month post-booster anti-HBs titers X10 and o10 mIU ml À 1 , respectively. To investigate the association between HLA-DPB1 and the kinetics of post-booster anti-HBs titers, we calculated the decay rate of anti-HBs as the ratio of 1-year to 1-month post-booster anti-HBs titers in booster responders. To obtain stable estimates, we used the 30th percentile of the distribution of ratio in booster responders as the cutoff value. A ratio of o1/10 was defined as fast decay.
Our previous study showed that HLA-DPB1 02:01:02, 02:02, 03:01:01, 04:01:01 and 14:01 alleles were significantly associated with decreased ORs of having undetectable post-booster anti-HBs levels. For HLA-DPB1 05:01 and 09:01 alleles, the ORs were significantly elevated. However, their effects on the kinetics of post-booster anti-HBs levels were unclear. Therefore, we temporarily defined these alleles as cluster I and cluster II alleles, respectively.
Statistical analysis
We used Pearson's w 2 -test to assess whether there were significant associations of post-booster anti-HBs levels with the subject's characteristics and HLA-DPB1 alleles or genotypes. Additionally, as the distribution of post-booster anti-HBs titers was severely skewed to the right, anti-HBs titers were logarithmically transformed for calculating geometric mean titer, and comparisons of GMTs among different groups were made using Student's t and F tests. Multivariate linear regression analyses for logarithmically transformed post-booster anti-HBs titers were used to estimate the effects of HLA-DPB1 alleles or genotypes and other potential predictors. We also used unconditional logistic regression to calculate adjusted odds ratio and its 95% CI of fast anti-HBs decay for specific HLA-DPB1 alleles or genotypes.
